Cancer immunoprevention: tracking down persistent tumor antigens
about
sameAs
The Promise of Preventive Cancer VaccinesHuman Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune responseCancer immunopreventionConcordant morphologic and gene expression data show that a vaccine halts HER-2/neu preneoplastic lesionsTumor Therapy Applying Membrane-bound Form of Cytokines.Gene expression analysis of immune-mediated arrest of tumorigenesis in a transgenic mouse model of HER-2/neu-positive basal-like mammary carcinoma.Immunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option?Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides.Advances in prophylactic cancer vaccine research.Oncoantigens for an immune prevention of cancer.A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumorsAdenovirus as vehicle for anticancer genetic immunotherapy.A biotherapy based on PSCs-in-3D spheroid-ameliorated biologics depletes in vivo cancer-sustaining stem cells.A limited autoimmunity to p185neu elicited by DNA and allogeneic cell vaccine hampers the progression of preneoplastic lesions in HER-2/NEU transgenic mice.Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive CancersImmunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation.Imiquimod and S-27609 as adjuvants of DNA vaccination in a transgenic murine model of HER2/neu-positive mammary carcinoma.Anti‐tumor immunity induced by tumor cells express a membrane‐bound form of IL‐2 and SDF‐1
P2860
Q26783742-029F4F10-4237-4800-8E98-D74644118588Q28251022-55666B3A-1B5D-40E8-8AEF-29BAE4187027Q28303393-06B83D8E-0B4D-4FDD-9846-CF78E1A830F8Q30909247-B660B48C-2D4A-4190-8BFC-557DFA7CFAC6Q33631960-B7DDD27C-B408-4629-8B26-9A5474E888F0Q35083847-87AC1CE6-4D59-4174-AE7F-BC82371172B7Q35142329-5EA3016F-A7B4-438E-8C6B-D78DA61B2B87Q35160569-622BD618-9603-408A-982B-E497322E85C2Q35204975-7FC97D95-5C42-4BB7-8A7D-3987A4094BECQ35232253-85ED12D7-B8C2-4759-ADD7-E9DB0B0297FCQ35918770-16E3BF68-84DB-42A9-802C-FAFC9654E70CQ36288930-9E171289-AAA1-4D5F-8005-5DC7E5621BEEQ36562161-5EC8D564-0AEB-4333-B5C1-4973043197A3Q40423857-39ED3C81-8311-4857-BCA2-0BB7651AFFF1Q40674386-F7C390E5-803D-483A-BC84-DCAB0BD383A4Q42427577-517580F4-4ED0-4111-BB68-FB3B48B0A233Q45884086-4A951249-9593-475C-A7E8-D09329CD1A1FQ58286987-988878A1-A56B-4A56-BBDD-BB139EF8420E
P2860
Cancer immunoprevention: tracking down persistent tumor antigens
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Cancer immunoprevention: tracking down persistent tumor antigens
@ast
Cancer immunoprevention: tracking down persistent tumor antigens
@en
Cancer immunoprevention: tracking down persistent tumor antigens
@nl
type
label
Cancer immunoprevention: tracking down persistent tumor antigens
@ast
Cancer immunoprevention: tracking down persistent tumor antigens
@en
Cancer immunoprevention: tracking down persistent tumor antigens
@nl
prefLabel
Cancer immunoprevention: tracking down persistent tumor antigens
@ast
Cancer immunoprevention: tracking down persistent tumor antigens
@en
Cancer immunoprevention: tracking down persistent tumor antigens
@nl
P1433
P1476
Cancer immunoprevention: tracking down persistent tumor antigens
@en
P2093
Guido Forni
P356
10.1016/S1471-4906(02)00030-3
P407
P577
2003-02-01T00:00:00Z